Search Results - "Lassere, Marissa N"

The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints by Lassere, Marissa N

“…There are clear advantages to using biomarkers and surrogate endpoints, but concerns about clinical and statistical validity and systematic methods to evaluate…”
Get full text

A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials by Hunter, David J, Losina, Elena, Guermazi, Ali, Burstein, Deb, Lassere, Marissa N, Kraus, Virginia

“…This narrative review outlines the work done in other fields with regards biomarker validation and qualification and the lessons that we may learn from this…”
Get more information

Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES) by Lassere, Marissa N, Johnson, Kent R, Schiff, Michal, Rees, David

“…Blood pressure is considered to be a leading example of a valid surrogate endpoint. The aims of this study were to (i) formally evaluate systolic and diastolic…”
Get full text

Musculoskeletal ultrasound including definitions for ultrasonographic pathology by WAKEFIELD, Richard J, BALINT, Peter V, KANE, David, O'CONNOR, Philip J, MANGER, Bernhard, JOSHUA, Fred, KOSKI, Juhani, GRASSI, Walter, LASSERE, Marissa N. D, SWEN, Nanno, KAINBERGER, Franz, KLAUSER, Andrea, SZKUDLAREK, Marcin, OSTERGAARD, Mikkel, BROWN, Andrew K, MACHOLD, Klaus P, CONAGHAN, Philip G, FILIPPUCCI, Emilio, BACKHAUS, Marina, D'AGOSTINO, Maria-Antonietta, SANCHEZ, Esperanza Naredo, IAGNOCCO, Annamaria, SCHMIDT, Wolfgang A, BRUYN, George

“…Ultrasound (US) has great potential as an outcome in rheumatoid arthritis trials for detecting bone erosions, synovitis, tendon disease, and enthesopathy. It…”
Get full text

Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema by Marissa N Lassere, Kent R Johnson, Maarten Boers, Peter Tugwell, Peter Brooks, Lee Simon, Vibeke Strand, Philip G Conaghan, Mikkel Ostergaard, Walter P Maksymowych, Robert Landewe, Barry Bresnihan, Paul-Peter Tak, Richard Wakefield, Philip Mease, Clifton O Bingham, 3rd, Michael Hughes, Doug Altman, Marc Buyse, Sally Galbraith, George Wells

“…OBJECTIVE: There are clear advantages to using biomarkers and surrogate endpoints, but concerns about clinical and statistical validity and systematic methods…”
Get full text

Surrogate endpoint metaregression: useful statistics for regulators and trialists by Baker, Stuart G., Lassere, Marissa N.D., Lo, Wang Pok

“…The main purpose of using a surrogate endpoint is to estimate the treatment effect on the true endpoint sooner than with a true endpoint. Based on a…”
Get full text

Clinicians adopting evidence based guidelines: a case study with thromboprophylaxis by Chapman, Nicola H, Lazar, Steven P, Fry, Margaret, Lassere, Marissa N, Chong, Beng H

“…Venous Thromboembolism (VTE) is a cause of hospital mortality and managing its morbidity is associated with significant expenditure. Uptake of evidenced based…”
Get full text

LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE) by Johnson, Kent R, Freemantle, Nick, Anthony, Danielle M, Lassere, Marissa N.D

“…Abstract Objective We describe a new statistical method called the surrogate threshold effect (STE) that estimates the threshold level of a surrogate needed in…”
Get full text

Imaging: the need for standardization by Lassere, Marissa N., MB, BS, Grad Dip Epi, PhD

“…The five stages in the evolution of a new method or measure are discovery (by design or inadvertent), development, testing, standardization and application…”
Get full text

COVID-19 vaccine hesitancy in inflammatory arthritis patients: serial surveys from a large longitudinal national Australian cohort by McMaster, Christopher, Liew, David F L, Lester, Susan, Rischin, Adam, Black, Rachel J, Chand, Vibhasha, Fletcher, Ashley, Lassere, Marissa N, March, Lyn, Robinson, Philip C, Buchbinder, Rachelle, Hill, Catherine L

“…Abstract Objectives To determine COVID-19 vaccine hesitancy rates in inflammatory arthritis patients and identify factors associated with changing vaccine…”
Get full text

Bias, coverage, and asymptotic behaviour of random effects meta-analysis: a clinically driven simulation study by Johnson, Kent, Hayen, Andrew, Lassere, Marissa N.D., Mengersen, Kerrie

“…The study of foundational features of meta-analysis is incomplete and continues to remain important. Using simulations we study bias and coverage and the…”
Get full text

The evidence for magnetic resonance imaging as an outcome measure in proof-of-concept rheumatoid arthritis studies by CONAGHAN, Philip G, MCQUEEN, Fiona M, GENANT, Harry K, ØSTERGAARD, Mikkel, PETERFY, Charles G, LASSERE, Marissa N. D, EJBJERG, Bo, BIRD, Paul, O'CONNOR, Philip J, HAAVARDSHOLM, Espen, EDMONDS, John P, EMERY, Paul

“…Magnetic resonance imaging (MRI) has now been used extensively in cross-sectional and observational studies as well as in controlled clinical trials to assess…”
Get full text

Minimal disease activity for rheumatoid arthritis: a preliminary definition by WELLS, George A, BOERS, Maarten, EMERY, Paul, FELSON, David T, FRANSEN, Jaap, FURST, Dan E, HAZES, Johanna M. W, JOHNSON, Kent R, KIRWAN, John R, LANDEWE, Robert B. M, LASSERE, Marissa N. D, MICHAUD, Kaleb, SHEA, Beverley, SUAREZ-ALMAZOR, Maria, SILMAN, Alan J, SMOLEN, Josef S, VAN DER HEIJDE, Desiree M. F. M, VAN RIEL, Piet L. C. M, WOLFE, Fred, TUGWELL, Peter S, BROOKS, Peter M, SIMON, Lee S, STRAND, C. Vibeke, ALETAHA, Daniel, ANDERSON, Jennifer J, BOMBARDIER, Claire, DOUGADOS, Maxime

“…Agreement on response criteria in rheumatoid arthritis (RA) has allowed better standardization and interpretation of clinical trial reports. With recent…”
Get full text

Magnetic resonance imaging in rheumatoid arthritis advances and research priorities by ØSTERGAARD, Mikkel, MCQUEEN, Fiona M, EMERY, Paul, EDMONDS, John P, CONAGHAN, Philip G, BIRD, Paul, EJBJERG, Bo, LASSERE, Marissa N. D, PETERFY, Charles G, O'CONNOR, Philip J, HAAVARDSHOLM, Espen, SHNIER, Ron, GENANT, Harry K

“…This article updates the work and results of the OMERACT MRI in RA Working Group as presented at the OMERACT 7 meeting in May 2004, focusing on the development…”
Get full text

Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update by LASSERE, Marissa N. D, JOHNSON, Kent R, TUGWELL, Peter S, WOODWORTH, Thasia G, BROOKS, Peter M, BOERS, Maarten, CARLTON, Kerri, DAY, Richard O, DE WIT, Marten, EDWARDS, I. Ralph, FRIES, James F, FURST, Daniel E, KIRWAN, John R

“…A presentation, demonstration, and discussion of recently developed adverse event instruments were the topics for the OMERACT 7 Drug Safety Module. The module…”
Get full text

Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two‐year prospective study (the DAMAGE study cohort) by Kirkham, Bruce W., Lassere, Marissa N., Edmonds, John P., Juhasz, Katherine M., Bird, Paul A., Lee, C. Soon, Shnier, Ron, Portek, Ian J.

“…Objective The primary aim of this prospective 2‐year study was to explain the wide variability in joint damage progression in patients with rheumatoid…”
Get full text

Generic patient self-report and investigator report instruments of therapeutic safety and tolerability by LASSERE, Marissa N. D, JOHNSON, Kent R, VAN SANTEN, Susanne, CARLTON, Kerri, RAPPO, Joy, MICHAEL, Rachel, KIRWAN, John R, EDMONDS, John P

“…A patient self-report instrument was designed as a patient event index that maps to a parallel investigator instrument. Event importance (a composite of…”
Get full text

Challenges and progress in adverse event ascertainment and reporting in clinical trials by LASSERE, Marissa N. D, JOHNSON, Kent R, WOODWORTH, Thasia G, FURST, Daniel E, FRIES, James F, KIRWAN, John R, TUGWELL, Peter S, DAY, Richard O, BROOKS, Peter M

“…Toxicity, safety, and tolerability are integral facets of patient risk/benefit decisions, yet the capacity to define, measure, and compare these aspects is…”
Get full text

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies by Johnson, Kent R, Lassere, Marissa N. D

Get full text

A critical appraisal of quantitative arthroscopy as an outcome measure in osteoarthritis of the knee by Oakley, Stephen Philip, Lassere, Marissa N

“…Background and Objectives: To review the performance of arthroscopic assessment of articular cartilage damage in osteoarthritis. Methods: The literature was…”
Get full text